<http://webisa.webdatacommons.org/prov/299510941>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/74442453> .
<http://webisa.webdatacommons.org/74442453>	<http://www.w3.org/ns/prov#value>	"Appropriate laboratory testing prior to initiating therapy and monitoring for hepatotoxicity during therapy with TIVICAY are recommended in patients with underlying hepatic disease such as hepatitis B or C." .
<http://webisa.webdatacommons.org/prov/299679078>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/74442453> .
<http://webisa.webdatacommons.org/74442453>	<http://www.w3.org/ns/prov#wasQuotedFrom>	<nih.gov> .
<http://webisa.webdatacommons.org/74442453>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/prov#Entity> .